PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a phase II study assessing response rate to PF-06463922 in patients with ROS1
translocation resistant to previous crizotinib therapy. Eligible patients will be treated
with the study drug until disease progression, unacceptable toxicity or patient refusal.
Disease assessment will be performed every 8 weeks according to RECIST criteria.
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione Ricerca Traslazionale
Collaborators:
Clinical Research Technology S.r.l. Clinical research technology Srl